Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-based HIV-1 integrase inhibitor design: a future perspective.

N Neamati1

  • 1University of Southern California, School of Pharmacy, 1985 Zonal Avenue, PSC 304BA, Los Angeles, CA 90089-9121, USA. neamati@usc.edu

Expert Opinion on Investigational Drugs
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.

British journal of cancer·2015
Same author

Retroviral integrase : a novel target in antiviral drug development and basic in vitro assays with the purified enzyme.

Methods in molecular medicine·2011
Same author

An approach to the stereo-controlled synthesis of polycyclic derivatives of l-4-thiazolidinecarboxylic acid active against HIV-1 integrase.

European journal of medicinal chemistry·2006
Same author

Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.

International journal of oncology·2006
Same author

A small-molecule antagonist of virion assembly.

Expert opinion on investigational drugs·2002
Same author

In vitro human immunodeficiency virus type 1 integrase assays.

Methods in enzymology·2001

Developing drugs that inhibit HIV-1 integrase (IN) is crucial for effective combination therapy. This review focuses on IN inhibitors, addressing the gap in clinically useful agents targeting this essential HIV enzyme.

Area of Science:

  • Virology
  • Drug Discovery
  • Structural Biology

Background:

  • The pol gene of HIV-1 encodes essential enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN).
  • FDA-approved drugs target PR and RT, demonstrating successful combination chemotherapy for HIV-1.
  • Currently, no clinically effective drugs inhibit HIV-1 integrase (IN).

Purpose of the Study:

  • To review inhibitors targeting HIV-1 integrase (IN).
  • To highlight the need for IN inhibitors to complement existing PR and RT therapies.
  • To discuss the challenges and recent progress in structure-based design for IN inhibitors.

Main Methods:

  • Review of existing literature on HIV-1 integrase inhibitors.
  • Analysis of structural information and drug binding sites for IN.

Related Experiment Videos

  • Comparison with structure-guided design successes for HIV-1 protease (PR) and reverse transcriptase (RT) inhibitors.

    • Main Results:

    • Significant advancements in structure-guided drug design have yielded numerous PR and RT inhibitors.
    • Structure-based inhibitor design for IN has lagged due to enzyme complexity and limited structural data.
    • Emerging structural information offers potential for future IN inhibitor development.

    Conclusions:

    • Combination therapy targeting all three HIV-1 enzymes (PR, RT, IN) is a promising strategy.
    • Development of effective IN inhibitors is critical to enhance current HIV-1 treatment regimens.
    • Recent progress in structural biology may soon enable structure-based design of novel IN inhibitors.